Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus PORTIA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus PORTIA 28.
CYCLAFEM 1/35 vs PORTIA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Category C
Category C
Oral Contraceptive
Oral Contraceptive